These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15489160)

  • 1. Combating susceptibility to drug resistance: lessons from HIV-1 protease.
    King NM; Prabu-Jeyabalan M; Nalivaika EA; Schiffer CA
    Chem Biol; 2004 Oct; 11(10):1333-8. PubMed ID: 15489160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease.
    Foulkes-Murzycki JE; Scott WR; Schiffer CA
    Structure; 2007 Feb; 15(2):225-33. PubMed ID: 17292840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.
    Kolli M; Lastere S; Schiffer CA
    Virology; 2006 Apr; 347(2):405-9. PubMed ID: 16430939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
    Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
    J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
    J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamical Network of HIV-1 Protease Mutants Reveals the Mechanism of Drug Resistance and Unhindered Activity.
    Appadurai R; Senapati S
    Biochemistry; 2016 Mar; 55(10):1529-40. PubMed ID: 26892689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
    J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitor resistance update: where are we now?
    Kim R; Baxter JD
    AIDS Patient Care STDS; 2008 Apr; 22(4):267-77. PubMed ID: 18422460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.
    Sices HJ; Leusink MD; Pacheco A; Kristie TM
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1249-55. PubMed ID: 11559424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.
    Ross L; Liao Q; Gao H; Pham S; Tolson J; Hertogs K; Larder B; Saag MS
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1379-85. PubMed ID: 11679150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of drug resistance in HIV protease.
    Pawar SD; Freas C; Weber IT; Harrison RW
    BMC Bioinformatics; 2018 Oct; 19(Suppl 11):362. PubMed ID: 30343664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors.
    Lapins M; Wikberg JE
    J Chem Inf Model; 2009 May; 49(5):1202-10. PubMed ID: 19391634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 protease substrate-groove: Role in substrate recognition and inhibitor resistance.
    Laco GS
    Biochimie; 2015 Nov; 118():90-103. PubMed ID: 26300060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.